News Headlines Article

F.D.A. Postpones Rule on Breast Cancer Drug
New York Times

The Food and Drug Administration appears to have postponed an expected decision on whether to revoke the approval of the drug Avastin as a treatment for breast cancer.

Genentech, the manufacturer of the drug, said on Friday that the F.D.A. had extended its review period for three months because the company had submitted new data since an agency advisory panel have voted 12 to 1 in July that the approval should be rescinded.